Zitat:
..In studies targeting the general population, median corrected seroprevalence was 3.2% [IQR 1.0-6.4%] (Table 2). These studies included household and community samples (n = 83), residual sera (n = 39), and blood donors (n = 33), with median corrected seroprevalence of 3.5% [IQR 1.2-8.5%], 2.7% [IQR 1.0-4.3%], and 2.8% [IQR 0.9-6.8%], respectively (Supplementary Table 4). The median corrected seroprevalence in studies targeting specific populations was 5.4%, [IQR 1.5-18.4%] (Table 3). Notably, the median corrected seroprevalence was 6.3% [IQR 2.1-18.8%, n = 72 studies] in healthcare workers and caregivers and 6.3% [IQR 2.8-17.8%, n = 21 studies] in specific patient groups (e.g., cancer patients). Essential non-healthcare workers (e.g., first responders) had a median seroprevalence of 10.0% [IQR 1.8-26.3%, n=7 studies](Supplementary Table 4). Among high-income countries, the median corrected seroprevalence was 3.4% [IQR 1.3-6.3%]....
Seit 15, Tabelle3:
Zitat:
Median corrected seroprevalence [IQR](Central Europe, Eastern Europe, and Central Asia): 1.6% [1.1-5.2%]
Und, wo leben wir nochmal? Und die Franzosen?
Zitat:
Our review shows that SARS-CoV-2 seroprevalence remains low in the general population, indicating that many people remain susceptible to infection and suggesting that naturally-derived herd immunity is not achievable without substantial morbidity, mortality, and strain on health services. These findings also highlight the importance of remaining vigilant until effective vaccines are broadly available. There are clear population differences in SARS-CoV-2 burden, with certain marginalized (Black and Asian persons) and at-risk populations (health care workers, essential non-health care workers, specific patient groups, close contacts) disproportionately affected. Policy and decision makers need to better protect these groups to reduce inequity in the distribution and impact of COVID-19. Such differences may inform policy on vaccine distribution.